PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Password Reminder
Not Registered? Click Here

Register

Register
It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
You are here: Manager factsheet

Gareth Powell
Polar Capital, Polar Capital Partners Ltd, Three Rock Capital Management
pdfIcon Manager factsheet pdf    rss feed RSS Feed
Manager profile
Gareth joined Polar Capital in 2007 to set up the healthcare team. He has over 22 years’ investment experience in the healthcare sector, with 14 years as a Portfolio Manager. Prior to Polar Capital, Gareth worked at Framlington, where he began his career in investment management in 1999. Soon afterwards, he joined the Healthcare Team in 2001 and helped launch the Framlington Biotech Fund, which he managed from 2004 until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder.
Total return for Gareth Powell
Manager career performance
Discrete calendar year performance : Gareth Powell

Manager career performance
Discrete performance
  0-12m 12-24m 24-36m 36-48m 48-60m 60-72m 72-84m 84-96m 96-108m 108-120m
Gareth Powell 21.2 -5.3 -0.3 15.9 10.5 0.9 12.0 9.1 13.0 11.8
Peer Group Composite 16.1 -12.0 -8.0 10.1 24.5 3.8 8.0 11.7 10.0 11.6
Over / Under 5.1 6.7 7.7 5.8 -14.0 -2.9 4.0 -2.6 3.0 0.2
Performance vs peer group composite: Gareth Powell
How a manager matches up against their peers gives you some idea of how talented they are. Very few managers perform equally well in rising and falling markets, so knowing which type of market a manager is capable of performing well within is also important.
 
Overall markets
Up
Outperformed peer group composite
7 years
out of a possible 10
 
Overall markets
Up
Underperformed peer group composite
3 years
out of a possible 10
 
Rising markets
UpDown
Outperformed peer group composite
5 years
out of a possible 8
 
Falling markets
UpDown
Outperformed peer group composite
2 years
out of a possible 2
Funds currently managed
Fund Sole/Co-managed Sector Periods
Polar Capital Healthcare Opportunities Lead manager FO Equity - Pharma Health & Biotech since Nov 30 2007 to present
Polar Capital Global Healthcare Trust PLC Co-managed IT Biotechnology & Healthcare since Jun 15 2010 to present
Future Healthcare Lead manager FO Equity - Pharma Health & Biotech since Apr 09 2021 to present
Funds managed previously
Fund Periods
PCGH ZDP PLC since Jun 20 2017 to Jun 14 2024
Polar Capital Healthcare Blue Chip since Sep 11 2014 to Jul 31 2019
AXA Framlington Biotech since Jan 01 2004 to Aug 31 2007
Polar Capital Biotechnology since Oct 31 2013 to Mar 31 2014
News & Research: Related articles sector Sector fund Fund group Group manager Manager
Group Two vital catalysts to lift the UK equity market: Being cheap is not enough By Matteo Anelli  20-Nov-2024
Group The ‘hidden gem’ funds you may not know yet By Patrick Sanders  20-Nov-2024
Group Mixed asset, equity income and Trump trades: The funds that investors have been eyeing in 2024’s second half By Gary Jackson  15-Nov-2024
Group What the Budget could mean for the UK economy, revisiting the investment case for AI and what Trump’s win means for policy, the economy, and markets: Thoughts from Fundswire this week By Diana Llewellyn  08-Nov-2024
Group Five funds to weather the storm of Trump’s second term By Matteo Anelli and Emma Wallis  08-Nov-2024
Sector Unicorn’s Peter Walls’ newest investment and favoured sectors By Emma Wallis  06-Nov-2024
Sector How Trustnet’s fund picks can beat the MSCI World by the end of 2024 By Jonathan Jones  25-Oct-2024
Sector High-risk investment trusts worth adding to your portfolio By Jonathan Jones  17-Oct-2024
Group The funds that have led the two-year bull market By Gary Jackson  15-Oct-2024
Group Scottish Mortgage replaced by commodities trust as most-bought on ii; Fundsmith gets back into the top 10 By Matteo Anelli  02-Oct-2024
Group Two-fund portfolios: The core/satellite approach By Matteo Anelli  30-Sep-2024
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

LATEST :

Five reasons to keep hold of your defensive funds

13:00 | Monday, January 20, 2014

Close

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close

© Trustnet Limited 2024. All Rights Reserved.
Please read our Terms of Use / Disclaimer and Privacy and Cookie Policy.
Data supplied in conjunction with Refinitiv and London Stock Exchange Plc